Clinical Drug Investigation

, Volume 33, Issue 3, pp 215–222

Effect of Add-on Pentoxifylline on Proteinuria in Membranous Glomerulonephritis: A 6-month Placebo-controlled Trial

  • Shirinsadat Badri
  • Simin Dashti-Khavidaki
  • Farrokhlegha Ahmadi
  • Mitra Mahdavi-Mazdeh
  • Mohammad-Reza Abbasi
  • Hossein Khalili
Original Research Article

DOI: 10.1007/s40261-013-0057-1

Cite this article as:
Badri, S., Dashti-Khavidaki, S., Ahmadi, F. et al. Clin Drug Investig (2013) 33: 215. doi:10.1007/s40261-013-0057-1

Abstract

Background

Membranous glomerulonephritis (MGN) may cause proteinuria as the main complication and is a strong risk factor for end-stage renal disease. Current therapeutic regimens provide only partial renoprotection. Data derived from both animal and human studies provide a scientific basis for the use of pentoxifylline as an antiproteinuric agent.

Objective

This study was designed to evaluate the antiproteinuric effect of add-on pentoxifylline therapy in non-diabetic patients with MGN.

Study Design

This was a double-blind, placebo-controlled trial.

Setting

Non-diabetic patients with histologically proven MGN and urinary protein excretion (UPE) >500 mg/24 h, entered a 6-month study period. Enrolled patients were selected from a university and three private clinics.

Intervention

Patients were assigned to one of the two treatment groups: pentoxifylline 400 mg two or three times a day, or matching placebo.

Main Outcome Measures

Baseline and follow-up assessments included estimated glomerular filtration rate (eGFR) and UPE. Differences in the changes in variables within the placebo and pentoxifylline treatment groups during the study period were assessed using Friedman’s test.

Results

Treatment with pentoxifylline for 6 months resulted in a significant reduction of mean UPE (p < 0.001) along with a slight, non-significant increase of eGFR, in comparison to the mean UPE and eGFR increase in the placebo group.

Conclusion

This study showed that add-on therapy of pentoxifylline in MGN was beneficial, and could be considered as a potential new therapeutic indication for the drug in such kidney diseases.

Supplementary material

40261_2013_57_MOESM1_ESM.pdf (34 kb)
Supplementary material 1 (PDF 34 kb)

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Shirinsadat Badri
    • 1
  • Simin Dashti-Khavidaki
    • 1
    • 2
  • Farrokhlegha Ahmadi
    • 2
  • Mitra Mahdavi-Mazdeh
    • 2
  • Mohammad-Reza Abbasi
    • 2
  • Hossein Khalili
    • 1
  1. 1.Department of Clinical Pharmacy, School of PharmacyTehran University of Medical SciencesTehranIran
  2. 2.Department of Nephrology, Nephrology Research CenterTehran University of Medical SciencesTehranIran